NASDAQ:CMPS COMPASS Pathways (CMPS) Stock Price, News & Analysis $4.22 -0.06 (-1.40%) Closing price 04:00 PM EasternExtended Trading$4.25 +0.03 (+0.71%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About COMPASS Pathways Stock (NASDAQ:CMPS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get COMPASS Pathways alerts:Sign Up Key Stats Today's Range$4.12▼$4.4050-Day Range$2.66▼$4.6252-Week Range$2.49▼$8.54Volume1.83 million shsAverage Volume846,832 shsMarket Capitalization$391.82 millionP/E RatioN/ADividend YieldN/APrice Target$18.83Consensus RatingBuy Company OverviewCOMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Read More… COMPASS Pathways Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreCMPS MarketRank™: COMPASS Pathways scored higher than 39% of companies evaluated by MarketBeat, and ranked 750th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCOMPASS Pathways has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCOMPASS Pathways has only been the subject of 4 research reports in the past 90 days.Read more about COMPASS Pathways' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for COMPASS Pathways are expected to grow in the coming year, from ($2.33) to ($1.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of COMPASS Pathways is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of COMPASS Pathways is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCOMPASS Pathways has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about COMPASS Pathways' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.78% of the float of COMPASS Pathways has been sold short.Short Interest Ratio / Days to CoverCOMPASS Pathways has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in COMPASS Pathways has recently increased by 2.20%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCOMPASS Pathways does not currently pay a dividend.Dividend GrowthCOMPASS Pathways does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.78% of the float of COMPASS Pathways has been sold short.Short Interest Ratio / Days to CoverCOMPASS Pathways has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in COMPASS Pathways has recently increased by 2.20%, indicating that investor sentiment is decreasing. News and Social Media3.3 / 5News Sentiment0.99 News SentimentCOMPASS Pathways has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for COMPASS Pathways this week, compared to 3 articles on an average week.Search Interest9 people have searched for CMPS on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows8 people have added COMPASS Pathways to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, COMPASS Pathways insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.25% of the stock of COMPASS Pathways is held by insiders.Percentage Held by Institutions46.19% of the stock of COMPASS Pathways is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about COMPASS Pathways' insider trading history. Receive CMPS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for COMPASS Pathways and its competitors with MarketBeat's FREE daily newsletter. Email Address CMPS Stock News HeadlinesCompass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare ConferenceMay 14, 2025 | finance.yahoo.comCompass Pathways Announces First Quarter 2025 Financial Results and Business HighlightsMay 9, 2025 | finance.yahoo.com“You all just got a lot richer”Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crashes. Do you think that’s an accident? When he threatens to “End the Fed” do you think he doesn’t know banking stocks will benefit? What about when he tells his followers, “Now is a good time to buy,” hours before relaxing tariffs and sending the market soaring? Is that an accident? Larry Benedict doesn’t think so. He thinks Trump knows what he’s doing… and believes he’s found the perfect tickers for everyday Americans to take advantage next time he triggers a big move.May 28, 2025 | Brownstone Research (Ad)Compass Pathways PLC (CMPS) Q1 2025 Earnings Call Highlights: Pivotal Phase 3 Trial Milestone ...May 9, 2025 | finance.yahoo.comCOMPASS Pathways plc (CMPS) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comCompass Pathfinder Limited: Compass Pathways Announces First Quarter 2025 Financial Results and Business HighlightsMay 8, 2025 | finanznachrichten.deCOMPASS Pathways ADS Q1 2025 Earnings PreviewMay 7, 2025 | msn.comWhy Compass Pathways Stock Was a Double-Digit Winner This WeekApril 25, 2025 | fool.comSee More Headlines CMPS Stock Analysis - Frequently Asked Questions How have CMPS shares performed this year? COMPASS Pathways' stock was trading at $3.78 at the start of the year. Since then, CMPS shares have increased by 11.6% and is now trading at $4.22. View the best growth stocks for 2025 here. How were COMPASS Pathways' earnings last quarter? COMPASS Pathways plc (NASDAQ:CMPS) posted its quarterly earnings data on Thursday, May, 8th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.03. Read the conference call transcript. When did COMPASS Pathways IPO? COMPASS Pathways (CMPS) raised $100 million in an IPO on Friday, September 18th 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI and Berenberg acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are COMPASS Pathways' major shareholders? Top institutional shareholders of COMPASS Pathways include Vivo Capital LLC (3.62%), Nantahala Capital Management LLC (3.05%), Millennium Management LLC (2.99%) and ARK Investment Management LLC (1.95%). Insiders that own company stock include Life Sciences NV Atai, Ekaterina Malievskaia and George Jay Goldsmith. View institutional ownership trends. How do I buy shares of COMPASS Pathways? Shares of CMPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of COMPASS Pathways own? Based on aggregate information from My MarketBeat watchlists, some other companies that COMPASS Pathways investors own include Symbotic (SYM), Enovix (ENVX), Rambus (RMBS), JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), Ginkgo Bioworks (DNA), Toast (TOST) and Saia (SAIA). Company Calendar Last Earnings5/08/2025Today5/28/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CMPS CIK1816590 Webwww.compasspathways.com Phone716-676-6461FaxN/AEmployees120Year Founded2016Price Target and Rating Average Stock Price Target$18.83 High Stock Price Target$45.00 Low Stock Price Target$11.00 Potential Upside/Downside+346.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$118.46 million Net MarginsN/A Pretax MarginN/A Return on Equity-63.85% Return on Assets-51.97% Debt Debt-to-Equity Ratio0.15 Current Ratio8.91 Quick Ratio8.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.65 per share Price / Book1.16Miscellaneous Outstanding Shares92,848,000Free Float65,513,000Market Cap$391.82 million OptionableOptionable Beta2.27 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:CMPS) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored“You all just got a lot richer”Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crash...Brownstone Research | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COMPASS Pathways plc Please log in to your account or sign up in order to add this asset to your watchlist. Share COMPASS Pathways With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.